Ipsen
Tracked across 5 events · 43 articles · First seen Apr 20, 2026 · Last active Aug 21, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Ipsen is acquiring Kartos Therapeutics, expanding its oncology pipeline with navtemadlin, a late-stage rare blood cancer asset. This acquisition is expected to contribute to Ipsen's core operating income from 2029.
Apr 20, 2026 · 7 articles
Business
Impact: Ipsen completed the acquisition of Memo Therapeutics, adding potravitug to its rare disease pipeline, which may drive future revenue growth.
Jul 01, 2026 · 16 articles
Business
Impact: Ipsen appointed Catherine Ashmore Bradley as an independent director, strengthening its board with financial expertise.
Jul 29, 2026 · 7 articles
Business
Ipsen announced on 21 August 2026 that it has completed the acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company. The acquisition adds navtemadlin, a late-stage MDM2 inhibitor in Phase III development for myelofibrosis, to Ipsen's…
Impact: Ipsen completed the acquisition, adding a promising late-stage asset to its pipeline. The deal strengthens its oncology franchise and may drive future revenue growth.
Aug 21, 2026 · 7 articles
Business
Impact: Ipsen is mentioned as Jenkins' former employer; no direct impact from this event.
Jul 15, 2026 · 6 articles
100
Ipsen acquired Kartos TherapeuticsIpsen completes Kartos...
ERGEN INTELLIGENCE
Track Ipsen live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard